위암 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Stomach Cancer Treatment Market is projected to record a 13.5% CAGR from 2024 to 2032, driven by an intensified emphasis on research and clinical trials.

Researchers are delving into novel therapies and treatment methodologies to bolster outcomes for stomach cancer patients. Clinical trials are at the forefront, evaluating groundbreaking drugs, targeted therapies, and personalized medicine strategies, all aimed at amplifying efficacy while minimizing side effects. These trials are also probing into innovative therapy combinations and advanced methodologies to curate more effective and customized treatment regimens. For example, in November 2023, the U.S. FDA broadened the scope of Pembrolizumab, approving it for stomach and esophageal junction cancer, thereby introducing a fresh therapeutic avenue for these patients.

The overall market is segregated into type, indication, drug class, route of administration, distribution channel, and region.

In terms of type, the immunotherapy segment in the stomach cancer treatment market will experience robust growth by 2032 led by the escalating imperative to bolster the body's immune response against cancer cells. Researchers are actively developing and evaluating diverse immunotherapy modalities, from checkpoint inhibitors to CAR-T cell therapy, all to enhance treatment outcomes. The mechanism of immunotherapy revolves around pinpointing specific proteins in cancer cells or tweaking immune cells for a more robust tumor attack. Furthermore, ongoing investigations are delving into combination therapies and tailored strategies to maximize efficacy while curtailing side effects.

By distribution channel, the stomach cancer treatment industry value from the specialty and retail pharmacies segment is projected to rise from 2024 to 2032. This surge is attributed to the increasing demand for a comprehensive range of therapies and ancillary support services. These pharmacies are not only dispensing specialized medications, such as targeted and immunotherapies but are also providing personalized patient counseling. Moreover, specialty pharmacies play a pivotal role in managing intricate treatments, ensuring patients receive their medications whilst offering essential monitoring and adherence support.

Regionally, the Asia Pacific stomach cancer treatment market size is projected to accrue robust growth between 2024 and 2032, fueled by rising healthcare investments. These investments are not just bolstering R and D but are also paving the way for groundbreaking therapies, including targeted treatments and immunotherapy. Furthermore, these financial boosts are facilitating the broadening of clinical trials and enhancing patient access to state-of-the-art treatments. As a culmination of these efforts, the region anticipates refined treatment methodologies, improved patient outcomes, and a wider reach of effective therapies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of stomach cancer
    • 3.2.1.2 Advancements in diagnostic techniques
    • 3.2.1.3 Development of targeted therapies
    • 3.2.1.4 Rising awareness and screening programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns associated with cancer therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy
• 5.3 Immunotherapy
• 5.4 Targeted therapy

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gastric cancer /gastroesophageal junction cancer
• 6.3 Gastrointestinal stromal tumors

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 PD-1/PD-L1 inhibitors
• 7.3 HER2 antagonists
• 7.4 VEGFR2 antagonists
• 7.5 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Specialty and retail pharmacies
• 9.4 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AstraZeneca PLC
• 11.2 Bristol Myers Squibb Company
• 11.3 Bayer AG
• 11.4 Biocon Limited
• 11.5 Celltrion Inc.
• 11.6 Eli Lilly and Company
• 11.7 F. Hoffmann-La Roche Ltd.
• 11.8 Ipsen Pharma
• 11.9 Merck and Co., Inc.
• 11.10 Novartis AG
• 11.11 Otsuka Holdings Co., Ltd.
• 11.12 Pfizer Inc.
• 11.13 Samsung Biologics Co., Ltd.
• 11.14 Teva Pharmaceutical Industries Ltd.
• 11.15 Viatris Inc.